More Cynata Therapeutics Limited news
Cynata Therapeutics LimitedASX: CYP

FDA Clears Cynata IND for Phase 2 Trial in GvHD

May 26, 2022 at 12:05 AM EDT · Issued by Cynata Therapeutics Limited

Filed with ASX · May 26, 2022 at 12:05 AM EDT

On 6ix: 6ix.com/news/fda-clears-cynata-ind-for-phase-2-trial-in-gvhd

Cynata Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Cynata Therapeutics Limited on 6ix

Story so far

  • Cynata Commences DFU Clinical TrialDec 22, 2021
  • Site Initiation Visit Completed for CYP DFU Clinical TrialNov 18, 2021
  • DSMB Recommends Continuation of Cynatas MEND TrialOct 8, 2021

Earlier from Cynata Therapeutics

  • Notice of Allowance for Cynata Chinese PatentFeb 27, 2022
  • Cynata Receives Decision to Grant a Patent in JapanJan 26, 2022
  • FUJIFILM Cellular Dynamics Executes Manufacturing AgreementDec 28, 2021
  • Cynata Commences DFU Clinical TrialDec 21, 2021
  • Site Initiation Visit Completed for CYP DFU Clinical TrialNov 17, 2021

Later from Cynata Therapeutics

  • Further data supports potency of Cynata MSCsJun 13, 2022
  • Pipeline Update Following Strategic Portfolio ReviewAug 11, 2022
  • Grant Award to Fund Study of Cynata MSCs in Heart DiseaseSep 25, 2022
  • Successful Completion of Planned DSMB Review of DFU TrialOct 11, 2022
  • Notice of Allowance for Australia & Canada Cymerus PatentsOct 16, 2022
All Cynata Therapeutics news releases↗

Follow Cynata Therapeutics into a list and get an email when it puts out news.

Follow Cynata Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer